NO931246L - Sammensetninger for behandling av infeksjon og sykdom foraarsaket av hepatites b virus (hbv) - Google Patents

Sammensetninger for behandling av infeksjon og sykdom foraarsaket av hepatites b virus (hbv)

Info

Publication number
NO931246L
NO931246L NO93931246A NO931246A NO931246L NO 931246 L NO931246 L NO 931246L NO 93931246 A NO93931246 A NO 93931246A NO 931246 A NO931246 A NO 931246A NO 931246 L NO931246 L NO 931246L
Authority
NO
Norway
Prior art keywords
hbv
virus
disease caused
compositions
hepatites
Prior art date
Application number
NO93931246A
Other languages
English (en)
Other versions
NO931246D0 (no
Inventor
Dennis W Adair
Kenneth A Smiles
Dannie King
Original Assignee
Oclassen Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oclassen Pharma Inc filed Critical Oclassen Pharma Inc
Publication of NO931246D0 publication Critical patent/NO931246D0/no
Publication of NO931246L publication Critical patent/NO931246L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Farmasosytiske sammensetninger nyttige for behandling av individer som lider av en infeksjon eller sykdom forårsaket av hepatit B virus (HBV) er beskrevet. Det er spesielt blitt oppdaget at administrering av lave dosemengder av l-(2'-deoksy-2'-fluoro-B-D-arabino- furanosyl)-5-iodouracil (FIAU) til mennsker som er kronisk infisert med HBV effektivt kan redusere drastisk sirkulerende markører assosiert med HBV. Fremgangsmåter for fremstilling av farmasøytiske antivirale sammensetninger er også beskrevet.
NO93931246A 1992-04-06 1993-03-31 Sammensetninger for behandling av infeksjon og sykdom foraarsaket av hepatites b virus (hbv) NO931246L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86389092A 1992-04-06 1992-04-06
US95292792A 1992-09-25 1992-09-25
US07/959,004 US5432165A (en) 1992-04-06 1992-10-09 Methods for the treatment of infection caused by Hepatitis B virus (HBV)

Publications (2)

Publication Number Publication Date
NO931246D0 NO931246D0 (no) 1993-03-31
NO931246L true NO931246L (no) 1993-10-07

Family

ID=27420427

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93931246A NO931246L (no) 1992-04-06 1993-03-31 Sammensetninger for behandling av infeksjon og sykdom foraarsaket av hepatites b virus (hbv)

Country Status (26)

Country Link
US (1) US5432165A (no)
EP (1) EP0565412A1 (no)
JP (1) JPH069403A (no)
CN (1) CN1081879A (no)
AP (1) AP372A (no)
AU (1) AU662804B2 (no)
BE (1) BE1009181A5 (no)
BR (1) BR9306207A (no)
CA (1) CA2092356A1 (no)
EE (1) EE9400068A (no)
ES (1) ES2105923B1 (no)
FR (1) FR2689398B1 (no)
GR (1) GR930100111A (no)
IL (1) IL105169A0 (no)
IT (1) IT1264332B1 (no)
LV (1) LV10191B (no)
MD (1) MD940152A (no)
MX (1) MX9301922A (no)
NO (1) NO931246L (no)
NZ (1) NZ247188A (no)
OA (1) OA10102A (no)
PH (1) PH31116A (no)
PT (1) PT101238A (no)
SI (1) SI9300144A (no)
WO (1) WO1993019762A1 (no)
YU (1) YU23993A (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6069252A (en) * 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6200952B1 (en) 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
WO1996010649A1 (en) * 1994-09-30 1996-04-11 Southwest Foundation For Biomedical Research Isolated human hepatitis b virus polymerase and uses thereof
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US6296882B1 (en) * 2000-06-12 2001-10-02 Manuel Viamonte, Jr. Non-toxic mucosal disinfectant containing isopropyl alcohol, sesame oil, and lemon oil
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
WO2010129947A2 (en) * 2009-05-08 2010-11-11 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE147774C (no) *
US4211773A (en) * 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
US4594339A (en) * 1982-04-06 1986-06-10 Sloan-Kettering Institute For Cancer Research Anti-herpes virus compositions containing 5-substituted 1-2'(deoxy-2-'-substituted-β-d-arabinofuranosyl)pyrimedene nucleosides
US4666892A (en) * 1984-03-06 1987-05-19 Sloan-Kettering Memorial Cancer Center Method and composition for hepatitis treatment with pyrimidine nucleoside compounds

Also Published As

Publication number Publication date
ITTO930226A1 (it) 1994-10-05
IL105169A0 (en) 1993-07-08
CN1081879A (zh) 1994-02-16
FR2689398A1 (fr) 1993-10-08
IT1264332B1 (it) 1996-09-23
NZ247188A (en) 1995-05-26
ES2105923A1 (es) 1997-10-16
OA10102A (en) 1996-12-18
YU23993A (sh) 1997-05-28
MD940152A (ro) 1995-12-31
NO931246D0 (no) 1993-03-31
AP9300513A0 (en) 1993-04-30
WO1993019762A1 (en) 1993-10-14
MX9301922A (es) 1993-10-01
PT101238A (pt) 1994-03-31
AP372A (en) 1994-11-24
BR9306207A (pt) 1998-06-23
US5432165A (en) 1995-07-11
PH31116A (en) 1998-02-28
SI9300144A (en) 1994-03-31
BE1009181A5 (fr) 1996-12-03
AU3530293A (en) 1993-10-07
AU662804B2 (en) 1995-09-14
GR930100111A (el) 1993-12-30
LV10191B (en) 1995-04-20
JPH069403A (ja) 1994-01-18
FR2689398B1 (fr) 1994-11-18
LV10191A (lv) 1994-10-20
ES2105923B1 (es) 1998-07-01
EE9400068A (et) 1995-12-15
CA2092356A1 (en) 1993-10-07
EP0565412A1 (en) 1993-10-13
ITTO930226A0 (it) 1993-04-05

Similar Documents

Publication Publication Date Title
MD1224B2 (en) Application of nucleoside analogues with 1,3-oxathiolan for treatment of hepatitis B
UA66744C2 (en) 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections
CA2081356A1 (en) Derivatives and analogues of 2-deoxy-2,3-didehydro-n- acetyl neuraminic acid and their use as antiviral agents
KR880010777A (ko) 바이러스 억제제와 결합한 dsRNA로 인간의 바이러스 감염을 치료하는 방법
WO2003063771A3 (en) N4-acylcytosine nucleosides for treatment of viral iinfections
NZ235244A (en) 2'-deoxy-2'-fluoro-ribonucleosides and compositions for the treatment of viral and parasitic diseases
DK0911033T4 (da) Anvendelse af konsensusinterferon til reduktion af bivirkningerne af interferonbehandling i viral hepatitis
EP1808434A3 (en) Use of 5-fluoro-2'-deoxy-3'-thiacytidine fo the treatment of hepatitis B
NO20073151L (no) Fremgangsmater og sammensetninger for a behandle hepatitt C virus
NO931246L (no) Sammensetninger for behandling av infeksjon og sykdom foraarsaket av hepatites b virus (hbv)
EP0270317A3 (en) Pharmaceutical compositions for the treatment of diseases caused by viruses
EP0293826A3 (en) Therapeutic and prophylactic application of sulfated polysaccharides against aids
DK92788A (da) Anvendelse af 3'-deoxy-3'-flourguanosider til fremstilling af laegemidler mod retrovira
ATE175873T1 (de) Weitere indolderivate mit antiviraler wirkung
EP0652011A4 (en) PROPHYLACTIC AGENT AND CURATIVE AGENT AGAINST VIRAL DISEASES OF THE RESPIRATORY TRACT.
MY127808A (en) Use of dideoxy nucleoside analogues in the treatment of viral infections
ATE157370T1 (de) Oligonukleotide mit wirkung gegen das respiratorische synzytial virus
BR9913333A (pt) Inibição e tratamento do vìrus da hepatite b e flavivìrus com helioxatina e seus análogos
DK0531413T3 (da) Et antiviralt præparat indeholdende prostratin
DE69823984D1 (de) Synthese und anti-hiv und anti-hepatitis virus aktivität von 1,3-oxaselenolan nucleosiden
EA199800526A1 (ru) Производные бензимидазола и их применение для лечения вирусных инфекций
DK0777669T3 (da) 4-[2-amino-6-(cyclopropylamino)-9H-purin-yl]-2-cyclopenten-1-methanolsuccinat som antiviralt middel
AP2001002181A0 (en) Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other toga viruses.
Eriksson et al. Is hypoxemia in cirrhotic patients due to a functional ‘hepato-pulmonal syndrome’?
KR960700741A (ko) 인터페론치료에 대한 무응답자의 c형 간염 치료방법(method of treating hepatitis c in non-pesponders to interferon treatment)